Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemic.
COVID-19
Healthcare workers
Hospital infection
Seroprevalence
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
18
12
2020
revised:
24
02
2021
accepted:
24
02
2021
pubmed:
2
3
2021
medline:
14
5
2021
entrez:
1
3
2021
Statut:
ppublish
Résumé
To estimate the SARS-CoV-2 antibody seroprevalence in healthcare workers (HCWs) at a university hospital in Mallorca, Spain. All HCWs received an e-mail inviting them to take part in the study. Participants had a nasopharyngeal swab test performed for reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) and serological tests to detect SARS-CoV-2 antibodies (primary study). Additionally, they were invited to complete a questionnaire on their exposure to COVID-19 individuals and their COVID-19-related symptoms (secondary study). Prevalence of antibodies (IgG, IgM, or both) and 95% confidence intervals (CIs) were calculated. Seventy-nine percent of the hospital's HCWs (N = 2210) took part in the primary study. Antibodies were detected in 61 participants, a prevalence of 2.8% (95% CI: 2.5-3.1). The prevalence was slightly higher in nurses (3.4%), registrars (3.9%), and wardens (3.4%). Thirty-nine percent of the primary study participants completed the secondary study questionnaire. Those with positive antibody test results had closer contact with COVID-19 individuals (60% vs. 92%; p < 0.001). After the first wave of the COVID-19 pandemic in Spain, the seroprevalence of SARS-CoV-2 antibodies in our university hospital HCWs was around 2.8%, which is slightly higher than the seroprevalence in the general population in our region. We believe it would be advisable to perform additional seroprevalence studies during the second wave of the epidemic.
Identifiants
pubmed: 33647507
pii: S1201-9712(21)00190-9
doi: 10.1016/j.ijid.2021.02.104
pmc: PMC7910131
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
482-486Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Clin Infect Dis. 2021 Oct 5;73(7):e1850-e1854
pubmed: 32803237
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Hosp Infect. 2020 Oct;106(2):357-363
pubmed: 32702465
J Med Virol. 2021 Feb;93(2):634-636
pubmed: 32761912
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
J Hosp Infect. 2020 Sep;106(1):102-106
pubmed: 32593608
JAMA Netw Open. 2020 May 1;3(5):e209673
pubmed: 32437576
Nutr Clin Pract. 2020 Oct;35(5):800-805
pubmed: 32668037
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Infect Dis. 2021 Apr 8;72(7):1244-1246
pubmed: 32743642
J Clin Virol. 2020 Aug;129:104511
pubmed: 32593133
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
Eur Geriatr Med. 2020 Oct;11(5):829-841
pubmed: 32671732
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
J Neurovirol. 2020 Oct;26(5):785-789
pubmed: 32666422
QJM. 2020 Aug 10;:
pubmed: 32777050
J Med Virol. 2021 Feb;93(2):916-923
pubmed: 32710669
JAMA Netw Open. 2020 May 1;3(5):e209666
pubmed: 32437575
Clin Infect Dis. 2021 May 4;72(9):1680-1681
pubmed: 32770224
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347